1. Business Highlights for the Three Months of 43rd Business Period (Fiscal Year Ending March 31, 2027)

(1) Qualitative Information on Consolidated Results of Operations

The Company finalized the provisional accounting treatments for the business combination during the six months ended September 30, 2025. Accordingly, the figures used for comparison with the three months ended June 30, 2025 have been adjusted to reflect the finalized accounting treatments.

During the three months ended June 30, 2026, the Japanese economy generally remained on a moderate recovery trend. Personal consumption gradually recovered against the backdrop of improvements in employment and income conditions and ongoing wage increases, while capital investment remained firm, particularly corporate investments in labor-saving and digitalization initiatives and in response to AI-related demand. Meanwhile, the outlook for the business environment remained uncertain due to persistently high raw material and energy prices, concerns about disruption to supply chains amid heightened tensions in the Middle East, rising interest rates accompanying the normalization of monetary policy, and continued uncertainty surrounding overseas economies and trade policies.

In the Information Infrastructure Business, cyber-attacks, including ransomware, have become increasingly sophisticated and elaborate, making the threat even more serious. In addition, while the rapid evolution of generative AI has led companies to make full-scale use of AI, the importance of protecting confidential information has increased, and strengthening AI governance has come to be recognized as a new management issue. Together with moves to strengthen legal regulations on data protection, these developments have positioned cybersecurity measures as a top priority for corporate management. Under these circumstances, demand for cybersecurity products and services remains high. In the Information Infrastructure Business, the Company's core business, we continued to see growing demand for cloud-based security measure products.

In the Application Services Business, business has been developing steadily in the CRM field thanks to collaboration with a major system integrator and telemarketing vendor. Additionally, revenue has been steadily increasing due to the growing adoption of subscription-based products. In collaboration with our capital and business alliance partner, Mobilus Corporation, we have also launched our in-house products that utilize generative AI technology. In the Software Quality Assurance field, demand remained strong for testing tools used to ensure the quality of enterprise systems and embedded software. In particular, with the further application of IT in automobiles, there was a strong need for improvement in the quality of embedded software such as in-vehicle software, and orders continued to be favorable. We also launched "Quomiru," a proprietary dashboard tool that visualizes progress, quality, and risks in the software development process in real time, attracting significant market interest. In the Business Solutions field, we secured bidding projects, etc. for independent administrative agencies, steadily accumulating orders. In the EdTech field, inquiries about our fully cloud-based school administration support system, "tsumugino," remained strong, resulting in a steady increase in new adoptions. In addition, following the adoption of "tsumugino" for "Benesse School Admin Cloud," the school administration support system offered by Benesse Corporation, new projects are being created through strengthened cooperation with Benesse.

In the Medical Systems Business, the new PSP Corporation ("PSP"), which was started on April 1, 2022, has been working to unify with our customer base and integrate with our products and services, as well as promoting the shift of PACS (picture archiving and communication systems for medical imaging management) to recurring revenue business models. PSP is actively advancing a shift from the on-premise PACS offered by the pre-merger PSP Corporation to cloud-based PACS at the time of renewal. In addition, to promote digitalization in the pathology field, we are working to expand into new market areas, including by strengthening collaboration with Medmain Inc., which became a subsidiary in April 2026.

As a result of the above, consolidated revenue for the three months ended June 30, 2026 was ¥18,885 million, a year-on-year increase of ¥3,021 million (19.0%), achieving a record high for the first three months. Gross profit amounted to ¥5,544 million, a year-on-year increase of ¥616 million (12.5%). Selling, general and administrative expenses were ¥3,966 million, a year-on-year increase of ¥307 million (8.4%), due to increases in personnel expenses and other costs. As a result, operating profit came to ¥1,606 million, a year-on-year increase of ¥335 million (26.4%).

Consequently, profit before tax was ¥1,622 million, a year-on-year increase of ¥344 million (26.9%), and profit attributable to owners of parent was ¥1,060 million, a year-on-year increase of ¥207 million (24.3%).

Results by operating segment were as follows:

1) Information Infrastructure Business

Results of the Information Infrastructure Business for the three months ended June 30, 2026 were strong thanks to orders for new projects, particularly those for subscription-based cloud cybersecurity measure products. Additionally, there was a steady accumulation of renewal orders. In addition to cloud-based security products, cross-selling progressed for AI-driven solutions that automate SOC*1 (Security Operation Center) operations. Revenue steadily increased thanks to the order backlog accumulated through the previous fiscal year and orders for new projects. Operating profit increased compared to the previous fiscal year, as the growth of the business covered the increased selling, general and administrative expenses. By product, in addition to cloud-based security measure products, e-mail security products designed to protect against attacks that use e-mail as an entry point for ransomware and solutions to manage vulnerabilities inherent in companies are increasingly being adopted.

At CROSS HEAD, orders received, revenue, and operating profit all exceeded the levels of the same period of the previous fiscal year, reflecting strong performance in e-mail security products.

At OCH Co., Ltd., orders received, revenue, and operating profit all exceeded the levels of the same period of the previous fiscal year, supported by orders for SG-ONE TANDEM, a new product in our UTM*2 (Unified Threat Management) lineup for small and medium-sized businesses.

At Firmus Sdn. Bhd., orders received exceeded the level of the same period of the previous fiscal year due to the acquisition of large projects and other factors. As a result, the accumulation of recurring revenue from subscription-based business contributed to revenue and operating profit exceeding the levels of the same period of the previous fiscal year.

As a result, revenue of the business amounted to ¥13,905 million, a year-on-year increase of ¥2,406 million (20.9%) , achieving a record high for the first three months. Operating profit amounted to ¥1,492 million, a year-on-year increase of ¥239 million (19.1%).

2) Application Services Business

Results of the Application Services Business for the three months ended June 30, 2026 exceeded those for the same period of the previous fiscal year for orders received, revenue, and operating profit.

In the CRM field, orders received, revenue, and operating profit all exceeded the levels of the same period of the previous fiscal year. Revenue increased thanks to the accumulation of subscription contracts secured to date, and operating profit significantly exceeded the level of the same period of the previous fiscal year.

In the Software Quality Assurance field, strong demand continued for testing tools for in-vehicle software. In addition, orders received, revenue, and operating profit all exceeded the levels of the same period of the previous fiscal year, thanks to the accumulated sales of subscription-based services.

In the Business Solutions field, orders received significantly exceeded the level of the same period of the previous fiscal year, as bidding projects progressed smoothly. Revenue and operating profit also exceeded the levels of the same period of the previous fiscal year, reflecting strong orders at the end of the previous fiscal year.

At ARECCIA Fintech Corp., orders received exceeded the level of the same period of the previous fiscal year, but revenue and operating profit fell short of the levels of the same period of the previous fiscal year.

At CASAREAL, Inc., orders received exceeded the level of the same period of the previous fiscal year, while revenue and operating profit fell short of the levels of the same period of the previous fiscal year due to a reactionary decline following large projects recorded in the same period of the previous fiscal year.

In the EdTech field, although orders received fell short of the level of the same period of the previous fiscal year, inquiries from public schools as well as private advanced schools continued to be strong. Revenue significantly exceeded the level of the same period of the previous fiscal year due to the introduction of the system at new schools, which had been progressing since the previous fiscal year. The operating loss increased as planned investments in product development, marketing, and increases in engineering and sales staff were implemented.

As a result, revenue of the business amounted to ¥2,574 million, a year-on-year increase of ¥271 million (11.8%). Operating profit amounted to ¥47 million (compared with an operating loss of ¥44 million in the same period of the previous fiscal year).

3) Medical Systems Business

For the three months ended June 30, 2026, the Medical Systems Business exceeded the levels of the same period of the previous fiscal year for orders received, revenue, and operating profit. Orders for "NOBORI," a cloud service for medical information, remained strong, and the cumulative number of contracting facilities increased. In addition, securing renewals from existing users without any attrition was a major factor. Revenue increased as the number of contracting facilities for PACS (medical imaging management) steadily increased and subscription revenue accumulated. Operating profit was negatively affected, as initially planned, by Medmain Inc., which became a consolidated subsidiary from the first three months and is currently in an investment phase; however, this impact was absorbed by higher revenue and improved profitability from expanded sales of cloud-based products. Upfront investments are continuing in projects such as the development of PHR[*3] (Personal Health Record) services targeted at general patients and the joint development with medical institutions, AI venture companies, and external partners to launch new businesses, and they have achieved strong results.

At Ichigo LLC, our medical-related consolidated subsidiary, orders received and revenue were on the same level as the same period of the previous fiscal year, while operating profit fell short of that level.

At A-Line Co., another medical-related consolidated subsidiary, orders received for MINCADI, a radiation dose management system, exceeded the level of the same period of the previous fiscal year as medical institutions are increasingly willing to invest in safety management systems for medical radiation. As a result, revenue and operating profit both exceeded the levels of the same period of the previous fiscal year.

As a result, revenue of the business amounted to ¥2,405 million, a year-on-year increase of ¥343 million (16.7%), while operating profit amounted to ¥66 million, a year-on-year increase of ¥3 million (6.2%).

(2) Qualitative Information on Consolidated Financial Position

Current assets decreased ¥2,189 million (2.2%) from March 31, 2026 to ¥99,215 million as of June 30, 2026. The principal factor in this change was a decrease of ¥4,723 million in cash and cash equivalents due to the acquisition of shares in Medmain Inc. Non-current assets stood at ¥23,779 million, an increase of ¥3,653 million (18.2%) from March 31, 2026. The principal factor in this change was a ¥2,658 million increase in goodwill. As a result, total assets amounted to ¥122,995 million, an increase of ¥1,463 million (1.2%) from March 31, 2026.

Current liabilities stood at ¥83,192 million, an increase of ¥411 million (0.5%) from March 31, 2026. The principal factor in this change was an increase of ¥1,584 million in contract liabilities. Non-current liabilities stood at ¥6,965 million, an increase of ¥895 million (14.7%) from March 31, 2026. The principal factor in this change was a ¥736 million increase in lease liabilities. As a result, total liabilities amounted to ¥90,157 million, an increase of ¥1,306 million (1.5%) from March 31, 2026.

Total equity was ¥32,837 million, an increase of ¥156 million (0.5%) from March 31, 2026. The principal factor in this change was an increase of ¥82 million in other components of equity. As a result, the ratio of equity attributable to owners of parent to total assets was 21.4%.

(3) Qualitative Information on Consolidated Financial Results Forecast and Other Forward-looking Statements

At this point, the financial results forecast is unchanged from the figures announced on May 8, 2026.

(Glossary)

*1	SOC	A SOC (Security Operation Center) is a specialized organization that monitors a company or organization’s networks and systems 24/7, collects and analyzes logs, and recommends countermeasures in response to security incidents.
*2	UTM	UTM (Unified Threat Management) is an approach that efficiently and comprehensively protects computer networks against threats such as computer viruses and hacking.
*3	PHR	A PHR (Personal Health Record) is a tool or system that allows individuals to manage and consolidate their personal health information.

2. Condensed Quarterly Consolidated Financial Statements and Primary Notes

(1) Condensed Quarterly Consolidated Statement of Financial Position

(Thousand yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	35,801,807	31,078,330
Trade and other receivables	7,035,359	5,709,521
Inventories	477,208	682,745
Advance payments to suppliers	42,323,403	45,241,188
Advance payment - cost of maintenance service	14,196,747	14,369,593
Other financial assets	324	22,226
Other current assets	1,570,369	2,112,116
Total current assets	101,405,220	99,215,722
Non-current assets		
Property, plant and equipment	5,426,692	6,262,834
Goodwill	4,509,910	7,168,053
Intangible assets	3,828,440	4,366,400
Investments accounted for using equity method	772,892	786,440
Other financial assets	3,234,694	2,778,154
Deferred tax assets	1,708,365	1,674,981
Other non-current assets	645,197	742,506
Total non-current assets	20,126,193	23,779,371
Total assets	121,531,414	122,995,093

(Thousand yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Trade and other payables	2,715,336	2,602,794
Borrowings	200,000	204,800
Lease liabilities	740,470	745,273
Income taxes payable	1,485,494	667,599
Contract liabilities	70,433,098	72,017,844
Other financial liabilities	2,438,984	2,349,811
Other current liabilities	4,767,224	4,604,256
Total current liabilities	82,780,609	83,192,380
Non-current liabilities		
Borrowings	1,550,000	1,510,800
Lease liabilities	1,678,513	2,415,190
Other financial liabilities	545,266	545,266
Retirement benefit liability	1,816,713	1,854,585
Provisions	169,217	169,555
Deferred tax liabilities	50,236	205,173
Other non-current liabilities	260,314	264,849
Total non-current liabilities	6,070,261	6,965,421
Total liabilities	88,850,870	90,157,801
Equity		
Share capital	1,298,120	1,298,120
Capital surplus	3,008,600	3,018,291
Treasury shares	(918,503)	(917,676)
Retained earnings	21,902,194	21,741,965
Other components of equity	1,036,916	1,119,476
Total equity attributable to owners of parent	26,327,327	26,260,177
Non-controlling interests	6,353,216	6,577,115
Total equity	32,680,543	32,837,292
Total liabilities and equity	121,531,414	122,995,093

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income

Condensed Quarterly Consolidated Statement of Profit or Loss

For the three months ended June 30

(Thousand yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Revenue	15,863,485	18,885,219
Cost of sales	(10,935,773)	(13,341,105)
Gross profit	4,927,711	5,544,113
Selling, general and administrative expenses	(3,659,133)	(3,966,336)
Other income	2,848	29,375
Other expenses	(423)	(563)
Operating profit	1,271,003	1,606,589
Finance income	18,851	49,050
Finance costs	(22,699)	(27,019)
Share of profit (loss) of investments accounted for using equity method	10,868	(6,359)
Profit before tax	1,278,024	1,622,260
Income tax expense	(389,886)	(517,294)
Profit	888,138	1,104,965
Profit attributable to:		
Owners of parent	853,659	1,060,684
Non-controlling interests	34,478	44,280
Earnings per share		
Basic earnings per share (Yen)	21.25	26.39
Diluted earnings per share (Yen)	21.18	26.30

Condensed Quarterly Consolidated Statement of Comprehensive Income

For the three months ended June 30

(Thousand yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Profit	888,138	1,104,965
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Equity financial assets measured at fair value through other comprehensive income	(97,016)	82,865
Total of items that will not be reclassified to profit or loss	(97,016)	82,865
Items that may be reclassified to profit or loss		
Cash flow hedges	3,801	16,309
Exchange differences on translation of foreign operations	12,118	47,679
Total of items that may be reclassified to profit or loss	15,919	63,988
Other comprehensive income, net of tax	(81,096)	146,854
Comprehensive income	807,042	1,251,820
Comprehensive income attributable to:		
Owners of parent	773,991	1,191,826
Non-controlling interests	33,050	59,993

(3) Notes to Condensed Quarterly Consolidated Financial Statements

(Notes on Going Concern Assumption)

Not applicable.

(Notes on Significant Changes in Shareholders' Equity)

Not applicable.

(Segment Information)

1) Overview of reportable segments

The Group's reportable segments are Group components for which separate financial information is available and subject to periodic review by the management to determine the allocation of management resources and evaluate business performance.

The Group has established a business division for each company's product/service, and each business division formulates comprehensive strategies for the product/service it handles and undertakes business activities based on these strategies.

Accordingly, the reportable segments of the Group comprise segments by product/service based on their business divisions, and the three reportable segments are the "Information Infrastructure Business," the "Application Services Business," and the "Medical Systems Business."

The Information Infrastructure Business comprises the Company and its subsidiaries CROSS HEAD, OCH Co., Ltd., Firmus Sdn. Bhd., Firmus Consulting Sdn. Bhd., and Firmus Pte. Ltd., and engages in the sale of network, security, storage products, etc., and provides integration as well as services involving maintenance, operations, monitoring, etc. The Application Services Business comprises the Company and its subsidiaries CASAREAL, Inc., ARECCIA Fintech Corp., TechMatrix Asia Holdings Co., Ltd., and TechMatrix Asia Co., Ltd. and provides business solutions, software quality assurance, system development for CRM face-to-face markets, application packages, cloud SaaS services, application and services with high added value such as tests. The Medical Systems Business comprises PSP Corporation, Ichigo LLC, A-Line Co., and Medmain Inc., and engages in the development/integration of medical-related software, cloud services, etc. for the medical market.

2) Information on reportable segments

The accounting methods for reportable segments are the same as the accounting policy for the preparation of the Group's Condensed Quarterly Consolidated Financial Statements. The profit figures of reportable segments are based on operating profit. Intersegment revenues are based on market prices.

For the three months ended June 30, 2025 (April 1, 2025 to June 30, 2025)

(Thousand yen)

	Reportable segment			Total	Adjustment (Note 1)	Amount reported in the Condensed Quarterly Consolidated Financial Statements
	Information Infrastructure Business	Application Services Business	Medical Systems Business			
Revenue						
Revenue from outside customers	11,498,420	2,302,724	2,062,339	15,863,485	–	15,863,485
Intersegment revenue	63,875	82,610	–	146,486	(146,486)	–
Total	11,562,296	2,385,335	2,062,339	16,009,971	(146,486)	15,863,485
Segment profit (loss) (Note 2)	1,253,443	(44,942)	62,501	1,271,003	–	1,271,003
Finance income						18,851
Finance costs						(22,699)
Share of profit (loss) of investments accounted for using equity method						10,868
Profit before tax						1,278,024

Notes: 1. Adjustment of intersegment revenue is the amount of elimination of intersegment transactions.
2. Total segment profit (loss) represents the amount of operating profit in the Condensed Quarterly Consolidated Statement of Profit or Loss.

For the three months ended June 30, 2026 (April 1, 2026 to June 30, 2026)

(Thousand yen)

	Reportable segment			Total	Adjustment (Note 1)	Amount reported in the Condensed Quarterly Consolidated Financial Statements
	Information Infrastructure Business	Application Services Business	Medical Systems Business			
Revenue						
Revenue from outside customers	13,905,191	2,574,268	2,405,759	18,885,219	–	18,885,219
Intersegment revenue	65,845	96,841	–	162,686	(162,686)	–
Total	13,971,036	2,671,110	2,405,759	19,047,906	(162,686)	18,885,219
Segment profit (Note 2)	1,492,969	47,238	66,380	1,606,589	–	1,606,589
Finance income						49,050
Finance costs						(27,019)
Share of profit (loss) of investments accounted for using equity method						(6,359)
Profit before tax						1,622,260

Notes: 1. Adjustment of intersegment revenue is the amount of elimination of intersegment transactions.
2. Total segment profit represents the amount of operating profit in the Condensed Quarterly Consolidated Statement of Profit or Loss.

(Business Combinations, etc.)

For the three months ended June 30, 2025 (April 1, 2025 to June 30, 2025)

Not applicable.

For the three months ended June 30, 2026 (April 1, 2026 to June 30, 2026)

(Business Combination through Share Acquisition)

With respect to the acquisition of shares of Medmain Inc. (hereinafter “Medmain”) announced in the “Notice Concerning Basic Agreement on Acquisition of Shares in Medmain to Make It a Consolidated Subsidiary” dated February 17, 2026, the Company and its consolidated subsidiary PSP Corporation (hereinafter “PSP”) resolved at a meeting of the Board of Directors held on April 24, 2026 to acquire the shares. Based on the share transfer agreement entered into on April 30, 2026, the Company and PSP additionally acquired 57.51% of Medmain’s shares on a voting-rights basis and made it a consolidated subsidiary.

1) Overview of the business combination

(i) Name and business activities of the acquiree

Name of acquiree: Medmain Inc.

Business activities: Planning, development, operation, and sale of AI software and cloud services supporting pathological diagnosis

(ii) Main reasons for the business combination

Since the capital and basic agreement reached on July 26, 2022, we have encouraged service development by merging Medmain’s pathological diagnosis technologies and systems, including AI development technology, with PSP’s cloud-based PACS, remote diagnostic imaging, and other technologies. As a result of discussions based on continuous technology development of the two companies, we have reached an agreement on a plan to evolve the development outcomes we have gained to the development and commercialization of a digital pathological diagnosis platform that highly integrates AI technology, through an even more unified organizational operation. With the significant change to the actual clinical use of pathological diagnosis support AI occurring soon, we aim to pursue business development at an even higher level as one, including securing a sustainable system for dealing with the medical device approval process and returning accumulated digital pathology data to medical research.

(iii) Acquisition date

April 30, 2026

(iv) Method used to obtain control of the acquiree

Acquisition of shares for cash consideration

(v) Percentage of voting equity interest acquired

Percentage of voting rights held immediately before the acquisition date: 14.54%

Percentage of voting rights additionally acquired on the acquisition date: 57.51%

Percentage of voting rights held after the acquisition: 72.05%

2) Consideration transferred for the acquiree and breakdown by type of consideration

	(Thousand yen)
Fair value of equity interest held immediately before the business combination	701,368
Cash	2,301,567
Total consideration transferred	3,002,936

Notes: 1. Acquisition-related costs for the business combination were ¥4,173 thousand and are included in "Selling, general and administrative expenses" in the Condensed Quarterly Consolidated Statement of Profit or Loss.

2. As a result of remeasuring the 14.54% equity interest in the acquiree held before the acquisition date at its acquisition-date fair value, the Group recognized a gain on a step acquisitions of ¥72,471 thousand. This gain is included in "Equity financial assets measured at fair value through other comprehensive income" in the Condensed Quarterly Consolidated Statement of Comprehensive Income.

3) Fair values of consideration transferred, assets acquired, and liabilities assumed at the acquisition date

	(Thousand yen)
Total consideration transferred	3,002,936
Cash and cash equivalents	135,577
Trade and other receivables (Note 1)	36,822
Property, plant and equipment	42,249
Intangible assets	549,856
Other assets	38,185
Total assets	802,691
Trade and other payables	84,692
Other liabilities	193,801
Total liabilities	278,494
Non-controlling interests (Note 2)	146,509
Goodwill (Notes 3 and 4)	2,625,249

Notes: 1. The contractual amount of trade and other receivables acquired was ¥36,822 thousand, and none of this amount is expected to be uncollectible.

2. Non-controlling interests are measured at the non-controlling shareholders' proportionate share of the fair value of the acquiree's identifiable net assets.

3. The assets acquired, liabilities assumed, and goodwill have been provisionally measured based on information currently available because the allocation of the consideration transferred had not been completed as of the end of the first quarter.

4. Goodwill mainly represents the excess earning capacity expected from expansion of the existing business resulting from the acquisition. No amount of goodwill is expected to be deductible for tax purposes.

4) Cash flows associated with the acquisition

	(Thousand yen)
Cash and cash equivalents paid for the acquisition	(2,301,567)
Cash and cash equivalents held by the acquiree at the acquisition date	135,577
Purchase of shares of the subsidiary	(2,165,990)

5) Impact on the Group's results

The Group's Condensed Quarterly Consolidated Statement of Profit or Loss includes revenue of ¥31,186 thousand and quarterly loss of ¥51,759 thousand generated by Medmain after the acquisition date.

Had the business combination occurred at the beginning of the period, the Group's revenue and profit for the three months ended June 30, 2026 would have been ¥18,894,679 thousand and ¥1,075,080 thousand, respectively. This pro forma information has not been audited.

(Notes on Quarterly Statement of Cash Flows)

Condensed Quarterly Consolidated Statement of Cash Flows has not been prepared for the three months ended June 30, 2026.

Meanwhile, depreciation and amortization for the three months ended June 30, 2025 and 2026 are as follows:

(Thousand yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Depreciation and amortization	675,422	760,776

(Significant Subsequent Events)

(Resolution on Repurchase and Cancellation of Treasury Shares)

At a meeting of the Board of Directors held on July 31, 2026, the Company resolved to acquire treasury shares pursuant to the provisions of Article 156 of the Companies Act, as applied with the replacement of terms under Article 165, Paragraph 3 of the Act, and to cancel treasury shares pursuant to the provisions of Article 178 of the Companies Act.

1. Reason for acquisition of treasury shares

The Company has decided to acquire treasury shares with the aim of further enhancing corporate value by improving capital efficiency and strengthening shareholder returns, taking into consideration growth investments for medium- to long-term earnings growth as well as its current cash position.

2. Details of the repurchase

(1) Class of shares to be repurchased	Common stock of the Company
(2) Total number of shares to be repurchased	Up to 2,300,000 shares (5.72% of the total number of issued shares (excluding treasury shares))
(3) Aggregate amount of repurchase costs	Up to ¥3,200,000,000
(4) Period of repurchase	From August 3, 2026 to February 25, 2027
(5) Method of repurchase	Market purchases on the Tokyo Stock Exchange

3. Details of the cancellation

(1) Class of shares to be cancelled	Common stock of the Company
(2) Total number of shares to be cancelled	Total number of treasury shares acquired pursuant to Item 2 above
(3) Scheduled cancellation date	March 31, 2027

Note: The number of shares to be cancelled will be determined after the completion of the acquisition of treasury shares pursuant to Item 2 above.

(Reference) The status of treasury shares as of June 30, 2026

Total number of issued shares (excluding treasury shares)	40,189,048 shares
Number of treasury shares	4,329,352 shares

3. Supplementary Information

Supplementary information on orders received and stock-type sales ratio

(1) Status of orders received

The status of orders received and order backlog of each segment during the three months ended June 30, 2026 is as follows.

Segment	Orders received (Million yen)	Order backlog (Million yen)
Information Infrastructure Business	16,253	81,229
Application Services Business	3,686	8,237
Medical Systems Business	2,973	20,077
Total	22,913	109,545

(2) Supplementary information on stock-type sales ratio

The stock-type sales ratio of each segment during the three months ended June 30, 2026 is as follows. Regarding the stock-type sales ratio, for the Information Infrastructure Business and the Application Services Business, non-consolidated figures for the Company are stated and for the Medical Systems Business, the figures for PSP Corporation, the consolidated subsidiary, are stated.

Segment	Stock-type net sales (Million yen)	Flow-type net sales (Million yen)	Stock-type sales ratio (%)
Information Infrastructure Business	10,376	1,259	89.2
Application Services Business	1,685	572	74.6
Medical Systems Business	1,606	648	71.3
Total	13,668	2,480	84.6